Tejas Patil is an Oncology physician affiliated with University of Colorado Cancer Center. OpenAlex indexes 185 publications with 3,542 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1665 Aurora Ct
Aurora, CO 800452517
Telephone
720-848-0000Provider last certified this registry record 12 Mar 2026.
Clinical trials
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Sponsor: Criterium, Inc.
- Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
- Partner Therapeutics, Inc.Program year20256 payments
- Eli Lilly and CompanyProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.9%Kinase inhibitor28.6%Tagrisso56%Alecensa21%Retevmo14%Lorbrena9%Part D<11 patientsOther antineoplastic agents2.3%Lumakras100%Part D<11 patientsNervous system
29.8%Phenothiazine9.7%Prochlorperazine Maleate100%Part D≥28 patientsOpioid Agonist9.2%Oxycodone Hcl71%Morphine Sulfate Er30%Part D<11 patients+ 4 more classes in this area
Blood & clotting
11.3%Factor Xa inhibitor11.3%Eliquis61%Xarelto39%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025
Journal of the National Comprehensive Cancer Network
2025 - Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bryan Haugen, MD
University of Colorado Cancer Center
Wells Messersmith, MD
University of Colorado Cancer Center
Thomas Flaig, MD
University of Colorado Cancer Center
Christopher Lieu, MD
University of Colorado Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”